Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) Receives Regulatory Approval For COVID-19 Vaccine in Younger Teenagers

Pfizer Inc (NYSE: PFE) and BioNTech SE received full regulatory authorization for their COVID-19 Vaccine for adolescents between 12 and 15 years in the US, which is a major milestone that will enable the drug manufacturers to continue marketing the vaccines to teenagers after the pandemic.

Pfizer’s COVID-19 vaccine approved for teens between 12-15 years

The Covid-19 Vaccine for teenagers 16 and older previously received official approval from the vaccine partners. The businesses said the Food and Drug Administration had granted their additional application to expand that authorization to younger teenagers in a statement released on Friday.

When it was given temporary approval for usage during the COVID-19 pandemic for the age group, the shot was first put into action. The businesses provided the FDA with additional data, including follow-up data from six months after the patients had finished the two-dose regimen, in order to receive full approval.

Now that the public health emergency has passed, the Vaccine’s manufacturers can continue to advertise and sell Comirnaty to private consumers and initiate marketing campaigns.

Pfizer and BioNTech commence a study on a universal COVID-19 vaccine 

The companies also have announced a new clinical study for a universal COVID-19 vaccine candidate in 2H 2022.

The broad effectiveness of universal vaccines versus many viral types is promised. They might be effective versus SARS-numerous CoV-2’s variations and require minimal if any, modifications over time. The press release states that the companies’ vaccine options would include pan-coronavirus injections that “protect against the broader family of viruses and its mutations” and T-cell boosting doses that guard against serious illness.

There are difficulties in developing a universal COVID-19 vaccination. Similarly to SARS-CoV-2 and other viruses, the main problem is that viruses, especially those with RNA genomes, have a propensity to change rapidly in order to elude defenses. If a virus is under pressure, such as through antibody exposure, viruses that can dodge those antibodies would preferentially multiply and take over. There are other changes that could happen in the viral genome, making it cause more infections.

Please make sure to read and completely understand our disclaimer at https://www.wallstreetpr.com/disclaimer. While reading this article one must assume that we may be compensated for posting this content on our website.

Published by Neha Gupta

Swati has worked in diverse capacities from financial research to currency trading in a span of 3 years.